心脏衰竭与癌症的联系:背景证据和研究前景
Edoardo Bertero1,2, Marco Canepa1, Christoph Maack2
1Cardiovascular Disease Unit, Ospedale Policlinico San Martino IRCCS & Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (E.B., M.C., P.A.).
Circulation
|October 26, 2018
概括
心力衰竭 (HF) 可能会增加癌症风险,尽管人们对同时发生和检测偏差存在担忧. 生物证据表明HF可能是一种致癌性疾病,促使进一步研究这一联系.
科学领域:
- 心脏病学
- 癌症学
- 翻译研究
背景情况:
- 流行病学研究表明,心力衰竭患者的癌症发病率较高.
- 这两种情况的高患病率和由于HF患者的密集医疗监测而增加的瘤检测是反驳的理由.
- 新出现的生物数据支持HF本身可能是一种致癌性疾病的假设.
研究的目的:
- 探索心力衰竭和癌症之间的潜在联系.
- 根据新的证据,重新评估现有的生物数据,表明HF与癌症诊断的增加有关.
- 调查潜在的生物途径连接HF和恶性瘤.
主要方法:
- 审查和重新评估现有的流行病学和生物研究.
- 考虑系统性因素,如低级炎症.
- 参考动物模型,证明HF对瘤生长的影响.
主要成果:
- 之前与癌症相关的神经激素激活现在被考虑在HF的背景下.
- 由低度炎症特征的系统性环境可能会导致HF和癌症.
- 动物研究表明后缺血性HF可以促进瘤生长.
结论:
- 心力衰竭与癌症之间的关系是一个新兴和重要的研究领域.
- 需要进一步的研究来确定心力衰竭是否积极促进癌症的发展.
- 了解这些联系可能会对患者护理和未来的研究方向产生影响.
相关概念视频
Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction
886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
Heart Failure VI: Adjunct Therapies
340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
Heart Failure V: Medical Management
319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319


